Trial · NCT00088530

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00088530, Phase 3, Completed, CTI BioPharma; results first posted 2017-06-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). Trials, record NCT00088530. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00088530

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT number: NCT00088530
Status: Completed
Phases: Phase 3
Enrollment: 140 participants, actual
Lead sponsor: CTI BioPharma
Conditions: Lymphoma, Non-Hodgkin
Interventions: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
First posted: 2004-07-29
Last updated: 2020-02-05
Results first posted: 2017-06-01

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Complete Response (CR) and Complete Response Unconfirmed (CRu)	EOT; approximately 6 months	Proportion of patients with a best response of complete response (CR) or Complete Response unconfirmed (CRu) in the End Of Treatment (EOT) or End Of Study (EOS) analyses by independent assessment in the Intent-to-treat (ITT) population through the End of Treatment (EOT)
Secondary	Progression-Free Survival (PFS)	18 months after 6 cycles of treatment; approximately 24 months	The time between the date of randomization and the date of the initial documentation of progressive/relapsed disease or death due to any cause.
Secondary	Overall Survival	18 months after 6 cycles of treatment; approximately 24 months	The time between the date of randomization and the date of death due to any cause.
Secondary	Overall Response Rate (ORR) Lasting at Least 4 Months	approximately 24 months	The proportion of patients with Complete response or Partial Response with a difference from the first documented objective response to disease progression or death of at least 4 months.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Complete Response (CR) and Complete Response Unconfirmed (CRu)	EOT; approximately 6 months	Intent to Treat (all randomized patients)	percentage of randomized patients	NUMBER
SECONDARY	Progression-Free Survival (PFS)	18 months after 6 cycles of treatment; approximately 24 months	Intent-to-treat patients	months	MEDIAN
SECONDARY	Overall Survival	18 months after 6 cycles of treatment; approximately 24 months	Intent-To-Treat (ITT) Population.	Months	MEDIAN
SECONDARY	Overall Response Rate (ORR) Lasting at Least 4 Months	approximately 24 months	Intent-To-Treat (ITT) population	participants	NUMBER

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Complete Response (CR) and Complete Response Unconfirmed (CRu)	Experimental Group	END OF TREATMENT: CR/CRu, n (%)	20.0	95% Confidence Interval 11.4 to 31.3	percentage of randomized patients
Complete Response (CR) and Complete Response Unconfirmed (CRu)	Comparator Group	END OF TREATMENT: CR/CRu, n (%)	5.7	95% Confidence Interval 1.6 to 14.0	percentage of randomized patients
Complete Response (CR) and Complete Response Unconfirmed (CRu)	Experimental Group	END OF STUDY: CR/CRu, n (%)	24.3	95% Confidence Interval 14.8 to 36.0	percentage of randomized patients
Complete Response (CR) and Complete Response Unconfirmed (CRu)	Comparator Group	END OF STUDY: CR/CRu, n (%)	7.1	95% Confidence Interval 2.4 to 15.9	percentage of randomized patients
Progression-Free Survival (PFS)	Experimental Group		5.3	95% Confidence Interval 2.3 to 6.2	months
Progression-Free Survival (PFS)	Comparator Group		2.6	95% Confidence Interval 1.9 to 3.5	months
Overall Survival	Experimental Group		10.2	95% Confidence Interval 6.4 to 15.7	Months
Overall Survival	Comparator Group		7.6	95% Confidence Interval 5.4 to 9.3	Months
Overall Response Rate (ORR) Lasting at Least 4 Months	Experimental Group		12		participants
Overall Response Rate (ORR) Lasting at Least 4 Months	Comparator Group		6		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Experimental Group	70
Overall Study	STARTED	Comparator Group	70
Overall Study	COMPLETED	Experimental Group	20
Overall Study	COMPLETED	Comparator Group	16
Overall Study	NOT COMPLETED	Experimental Group	50
Overall Study	NOT COMPLETED	Comparator Group	54

Source ClinicalTrials.gov

Adverse events262

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Experimental Group	21	68
other	Anemia	Blood and lymphatic system disorders	Comparator Group	22	67
other	Neutropenia	Blood and lymphatic system disorders	Experimental Group	34	68
other	Neutropenia	Blood and lymphatic system disorders	Comparator Group	16	67
other	Leukopenia	Blood and lymphatic system disorders	Experimental Group	17	68
other	Leukopenia	Blood and lymphatic system disorders	Comparator Group	7	67
other	Thrombocytopenia	Blood and lymphatic system disorders	Experimental Group	14	68
other	Thrombocytopenia	Blood and lymphatic system disorders	Comparator Group	13	67
other	Febrile Neutropenia	Blood and lymphatic system disorders	Experimental Group	6	68
other	Febrile Neutropenia	Blood and lymphatic system disorders	Comparator Group	2	67

1 to 10 of 262Source ClinicalTrials.gov

See all 262 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Experimental Group	49	68
Total, all-cause mortality	Comparator Group	52	67
Total, other adverse events	Experimental Group	66	68
Total, other adverse events	Comparator Group	61	67
Total, serious adverse events	Experimental Group	35	68
Total, serious adverse events	Comparator Group	30	67

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22652183	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Experimental Group vs Comparator Group: Overall Response Rate (ORR) Lasting at Least 4 Months	Trial comparisons
Experimental Group vs Comparator Group: deaths from any cause	Trial comparisons
Experimental Group vs Comparator Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00088530

GET https://conductscience.org/api/trials/v1/NCT00088530/events?page=2

API reference For AI assistants